Paying users zone. Data is covered by hidden.

  • Get to Allergan PLC for $15.99, or

  • get to entire website for at least 3 months from $49.99.


Visa Mastercard Maestro American Express Discover JCB    PayPal

Microsoft Excel LibreOffice Calc

Allergan PLC (AGN)


Statement of Cash Flows

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Allergan PLC, Consolidated Statement of Cash Flows

USD $ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income (loss) hidden hidden hidden hidden hidden
Depreciation hidden hidden hidden hidden hidden
Amortization hidden hidden hidden hidden hidden
Provision for inventory reserve hidden hidden hidden hidden hidden
Share-based compensation hidden hidden hidden hidden hidden
Deferred income tax benefit hidden hidden hidden hidden hidden
Pre-tax gain on sale of businesses to Teva hidden hidden hidden hidden hidden
Non-cash tax effect of gain on sale of businesses to Teva hidden hidden hidden hidden hidden
Goodwill impairments hidden hidden hidden hidden hidden
In-process research and development impairments hidden hidden hidden hidden hidden
Loss on asset sales and impairments, net hidden hidden hidden hidden hidden
Net income impact of other-than-temporary loss on investment in Teva securities hidden hidden hidden hidden hidden
Charge to settle Teva related matters hidden hidden hidden hidden hidden
Loss on forward sale of Teva shares hidden hidden hidden hidden hidden
Gain on sale of Teva securities, net hidden hidden hidden hidden hidden
Amortization of inventory step-up hidden hidden hidden hidden hidden
Gain on sale of businesses hidden hidden hidden hidden hidden
Non-cash extinguishment of debt hidden hidden hidden hidden hidden
Cash discount related to extinguishment of debt hidden hidden hidden hidden hidden
Amortization of deferred financing costs hidden hidden hidden hidden hidden
Contingent consideration adjustments, including accretion hidden hidden hidden hidden hidden
Excess tax benefit from stock-based compensation hidden hidden hidden hidden hidden
Impact of assets held for sale hidden hidden hidden hidden hidden
Other, net hidden hidden hidden hidden hidden
(Increase) decrease in accounts receivable, net hidden hidden hidden hidden hidden
(Increase) decrease in inventories hidden hidden hidden hidden hidden
(Increase) decrease in prepaid expenses and other current assets hidden hidden hidden hidden hidden
Increase (decrease) in accounts payable and accrued expenses hidden hidden hidden hidden hidden
Increase (decrease) in income and other taxes payable hidden hidden hidden hidden hidden
Increase (decrease) in other assets and liabilities hidden hidden hidden hidden hidden
Changes in assets and liabilities, net of effects of acquisitions hidden hidden hidden hidden hidden
Reconciliation to net cash provided by operating activities hidden hidden hidden hidden hidden
Net cash provided by operating activities hidden hidden hidden hidden hidden
Additions to property, plant and equipment hidden hidden hidden hidden hidden
Additions to product rights and other intangibles hidden hidden hidden hidden hidden
Sale of businesses to Teva hidden hidden hidden hidden hidden
Additions to investments hidden hidden hidden hidden hidden
Proceeds from sale of investments and other assets hidden hidden hidden hidden hidden
Payments to settle Teva related matters hidden hidden hidden hidden hidden
Proceeds from sales of property, plant and equipment hidden hidden hidden hidden hidden
Acquisitions of businesses, net of cash acquired hidden hidden hidden hidden hidden
Net cash (used in) provided by investing activities hidden hidden hidden hidden hidden
Proceeds from borrowings of long-term indebtedness, including credit facility hidden hidden hidden hidden hidden
Payments on debt, including capital lease obligations and credit facility hidden hidden hidden hidden hidden
Debt issuance and other financing costs hidden hidden hidden hidden hidden
Proceeds from issuance of preferred shares hidden hidden hidden hidden hidden
Proceeds from issuance of ordinary shares hidden hidden hidden hidden hidden
Payments of contingent consideration and other financing hidden hidden hidden hidden hidden
Proceeds from stock plans hidden hidden hidden hidden hidden
Proceeds from forward sale of Teva securities hidden hidden hidden hidden hidden
Payments to settle Teva related matters hidden hidden hidden hidden hidden
Repurchase of ordinary shares hidden hidden hidden hidden hidden
Dividends paid hidden hidden hidden hidden hidden
Excess tax benefit from stock-based compensation hidden hidden hidden hidden hidden
Net cash provided by (used in) financing activities hidden hidden hidden hidden hidden
Effect of currency exchange rate changes on cash and cash equivalents hidden hidden hidden hidden hidden
Movement in cash held for sale hidden hidden hidden hidden hidden
Net increase (decrease) in cash and cash equivalents hidden hidden hidden hidden hidden
Cash and cash equivalents at beginning of period hidden hidden hidden hidden hidden
Cash and cash equivalents at end of period hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18).

Item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Allergan PLC’s net cash provided by operating activities increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Allergan PLC’s net cash (used in) provided by investing activities declined from 2016 to 2017 but then slightly increased from 2017 to 2018.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Allergan PLC’s net cash provided by (used in) financing activities increased from 2016 to 2017 but then slightly declined from 2017 to 2018.